Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma.

Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma. Oncol Lett. 2018 May;15(5):7799-7805 Authors: Zhang HJ, Yuan GL, Liang QL, Peng XX, Cheng SA, Jiang L Abstract Radiotherapy is a vital treatment option for patients with nasopharyngeal carcinoma (NPC). Concurrent cisplatin-based radiochemotherapy with or without adjuvant chemotherapy had acquired good clinical effects with good local control rates. However, a number of patients present with metastasis following systemic regimens or initial diagnosis of locally advanced NPC, which cause difficulty for subsequent therapy. Therefore, there is an urgent requirement to discover novel targeted therapies. The present report describes one case of a patient with NPC and multiple metastases. The patient was treated with systemic therapy in combination with bevacizumab, palliative radiotherapy and chemotherapy following treatment with cetuximab and concurrent chemoradiotherapy in 2015. Following the addition of bevacizumab, metastases were reduced or disappeared after >2 months, and the duration of progression-free survival was 7 months. Bevacizumab is a monoclonal antibody that targets VEGF, and it is associated with angiogenesis, which causes the growth, invasion and progression of tumors. In previous studies, bevacizumab has been approved for the treatment of several types of malignant cancer and it has been able to effectively improv...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research